Axim Biotechnologies Inc
AXIM Biotechnologies, Inc. develops diagnostic healthcare solutions for ophthalmological conditions. It develops and commercializes two point-of-care diagnostic tests to assist eye-care physicians in detecting and quantifying biomarkers associated with aqueous deficient dry eye disease and non-specific allergic conjunctivitis, including ocular total immunoglobulin E allergy test and lactoferrin A… Read more
Axim Biotechnologies Inc (AXIM) - Net Assets
Latest net assets as of June 2025: $-10.43 Million USD
Based on the latest financial reports, Axim Biotechnologies Inc (AXIM) has net assets worth $-10.43 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($3.22 Million) and total liabilities ($13.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-10.43 Million |
| % of Total Assets | -323.39% |
| Annual Growth Rate | N/A |
| 5-Year Change | -765.44% |
| 10-Year Change | N/A |
| Growth Volatility | 51.65 |
Axim Biotechnologies Inc - Net Assets Trend (2011–2024)
This chart illustrates how Axim Biotechnologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Axim Biotechnologies Inc (2011–2024)
The table below shows the annual net assets of Axim Biotechnologies Inc from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-10.42 Million | -36.09% |
| 2023-12-31 | $-7.66 Million | -58.67% |
| 2022-12-31 | $-4.83 Million | -106.37% |
| 2021-12-31 | $-2.34 Million | -249.33% |
| 2020-12-31 | $1.57 Million | +123.16% |
| 2019-12-31 | $-6.76 Million | -11.16% |
| 2018-12-31 | $-6.08 Million | +3.22% |
| 2017-12-31 | $-6.28 Million | -164.99% |
| 2016-12-31 | $-2.37 Million | -39.90% |
| 2015-12-31 | $-1.70 Million | -191.91% |
| 2014-12-31 | $-580.72K | -518.34% |
| 2013-12-31 | $-93.92K | -1899.08% |
| 2012-12-31 | $-4.70K | -146.03% |
| 2011-12-31 | $10.21K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Axim Biotechnologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7569522400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $31.89K | % |
| Other Components | $65.25 Million | % |
| Total Equity | $-10.42 Million | 100.00% |
Axim Biotechnologies Inc Competitors by Market Cap
The table below lists competitors of Axim Biotechnologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fanhua Inc.
NASDAQ:AIFU
|
$975.10K |
|
Total Helium Ltd
OTCQB:TTLHF
|
$975.86K |
|
ACS (OCI1.SG)
STU:OCI1
|
$976.20K |
|
New Tech Capital S.A.
WAR:NTC
|
$976.53K |
|
Weizmann Limited
NSE:WEIZMANIND
|
$974.86K |
|
Mlabs Systems Bhd
KLSE:0085
|
$974.77K |
|
Black Widow Resources Inc
V:BWR
|
$974.69K |
|
Stockworks Gold Inc.
V:STW
|
$974.39K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Axim Biotechnologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -7,656,647 to -10,419,565, a change of -2,762,918.
- Net loss of 3,512,466 reduced equity.
- New share issuances of 221,685 increased equity.
- Other comprehensive income increased equity by 50.
- Other factors increased equity by 527,813.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.51 Million | -33.71% |
| Share Issuances | $221.69K | +2.13% |
| Other Comprehensive Income | $50.00 | +0.0% |
| Other Changes | $527.81K | +5.07% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Axim Biotechnologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | $0.00 | $0.00 | x |
| 2012-12-31 | $0.00 | $0.00 | x |
| 2013-12-31 | $0.00 | $0.00 | x |
| 2014-12-31 | $-0.02 | $0.00 | x |
| 2015-12-31 | $-0.05 | $0.00 | x |
| 2016-12-31 | $-0.06 | $0.00 | x |
| 2017-12-31 | $-0.12 | $0.00 | x |
| 2018-12-31 | $-0.11 | $0.00 | x |
| 2019-12-31 | $-0.11 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $-0.02 | $0.00 | x |
| 2022-12-31 | $-0.03 | $0.00 | x |
| 2023-12-31 | $-0.03 | $0.00 | x |
| 2024-12-31 | $-0.03 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Axim Biotechnologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4985.19%
- • Asset Turnover: 0.02x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-32.66%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | -27.38% | -27.94% | 0.14x | 7.08x | $-3.81K |
| 2012 | 0.00% | -34.39% | 0.33x | 0.00x | $-14.43K |
| 2013 | 0.00% | -411.77% | 0.38x | 0.00x | $-79.83K |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-524.87K |
| 2015 | 0.00% | -20539.22% | 0.04x | 0.00x | $-9.92 Million |
| 2016 | 0.00% | -12346.00% | 0.03x | 0.00x | $-5.57 Million |
| 2017 | 0.00% | -8761.70% | 0.02x | 0.00x | $-3.54 Million |
| 2018 | 0.00% | -3453.05% | 0.09x | 0.00x | $-6.15 Million |
| 2019 | 0.00% | -846.98% | 0.47x | 0.00x | $-6.10 Million |
| 2020 | -429.85% | 0.00% | -0.01x | 7.23x | $-6.89 Million |
| 2021 | 0.00% | -27320.76% | 0.01x | 0.00x | $-16.28 Million |
| 2022 | 0.00% | -67120.74% | 0.00x | 0.00x | $-5.47 Million |
| 2023 | 0.00% | -20394.96% | 0.01x | 0.00x | $-7.29 Million |
| 2024 | 0.00% | -4985.19% | 0.02x | 0.00x | $-2.47 Million |
Industry Comparison
This section compares Axim Biotechnologies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Axim Biotechnologies Inc (AXIM) | $-10.43 Million | -27.38% | N/A | $975.00K |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |